Trials Open to Enrollment

AIDS Clinical Trials: New Trials Open to Enrollment

http:/lwww. actis. org/actinewl. html

HIV-1 infection and who are unable to participate in another Viramune controlled clinical trial
and have a compelling need for anti-HIV treatment. For more information, view the Protocol
Database record.
E An International, Double Blind, Randomized, Phase III Study to Evaluate the
Tolerance, Safety, and Effectiveness of Viramune (Nevirapine) in Preventing Clinical
AIDS Progression Events or Death When Used in Combination With Lamivudine (3TC)
and Stable (>= 4 weeks) Background Nucleoside Therapy. FDA 200E. Drugs:
Zidovudine, Lamivudine. Antiretroviral, Saquinavir mesylate.
The purpose of this Boehringer Ingelheim Pharmaceuticals, Inc. sponsored study is to evaluate
the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression
events or death when used in combination with Lamivudine and background nucleoside
therapy. For more information, view the Protocol Database record.
tt E An Open Label, Non-Comparative Study of Saquinavir-SGC in combination with
Zidovudine (AZT) and Lamivudine (3TC) in the Treatment of HIV-1 Infected Patients
With No Previous Anti-Retroviral Drug Therapy. FDA 229F. Drugs: Zidovudine,
Lamivudine. Antiretroviral, Saquinavir mesylate.
The purpose of this Hoffmann - La Roche, Inc. sponsored study is to evaluate the efficacy of
Saquinavir-SGC combination with Zidovudine and Lamivudine in the treatment of HIV-1
infected patients with no previous anti-retroviral drug therapy. For more information, view the
Protocol Database record.
Q A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on
the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients who are
Receiving Standard Induction and Maintenance Therapy for this Infection. FDA 259A.
Drug: Nelfinavir.
The purpose of this Agouron Pharmaceuticals sponsored study is to evaluate the safety and efficacy
of Viracept in patients undergoing acute treatment for CMV retinitis. For more information, view
the Protocol Database record.
Q Viracept Expanded Access Program. FDA 259B. Drug: Nelfinavir.
The purpose of this Agouron Pharmaceuticals sponsored study is to make nelfinavir mesylate
(Viracept) available for treatment of HIV positive patients who are unable to take IDV (Crixivan)
and/or Ritonavir (Norvir) (because of failure, intolerance, or contraindication) and who have a
CD4 cell count of <= 100. To obtain additional information on the safety profile of nelfinavir
mesylate (Viracept). This program trial was amended on 1/8/97. For more information, view the
Protocol Database record.
D A Pilot, Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of
Viracept on the Clinical Outcome of Disseminated Mycobacterium avium Complex Disease
(MAC) in AIDS Patients who are Receiving Standard Acute Treatment for This
Opportunistic Infection. FDA 259C. Drug: Nelfinavir.
The purpose of this Agouron Pharmaceuticals sponsored study is to evaluate the safety and efficacy

O'T" e.e ( e e e ( " " e ika A d' d ".e" F

3of10

03/17/97 15:06:44